bluuebunny/crossref_metadata_2025_split huggingface dataset:
Bisdemethoxycurcumin inhibits oxidative stress and antagonizes Alzheimer's disease by up‐regulating SIRT1
Authors: Xu Yan , Hu Rong , He Duanqun , Zhou Guijuan , Wu Heng , Xu Chenlin , He Bing , Wu Lin , Wang Yilin , Chang Yunqian , Ma Rundong , Xie Ming , Xiao Zijian 
Published: May 2020

AbstractIntroductionAlzheimer's disease (AD) is a progressive neurodegenerative disease. It can lead to progressive cognitive impairment, memory loss, and behavioral alterations. So far, the exact cellular and molecular mechanisms underlying this disorder remain unclear. And there are no effective treatments to prevent, halt, or reverse AD. In recent years, Chinese traditional medicine has become a new force in the treatment of AD, and the typical representatives of natural herbal ingredients are curcumin and its derivatives. Bisdemethoxycurcumin (BDMC), which is a classical derivative of curcumin, was found to have neuroprotective effects against a cell model of Alzheimer's disease (AD) in our previous studies. This study investigated the intrinsic mechanism of BDMC against AD in animal models.MethodsIn this study, BDMC was injected into the lateral ventricles of normal C57BL/6 mice, APP/PS mice, and APP/PS mice treated with EX527 (the inhibitor of SIRT1). Y maze and Morris water maze were used to test the learning and memory ability of mice. Nissl staining was used to observe the morphological changes of neurons. Immunofluorescence staining was used to detect Aβ deposition in mice. The activities of GSH and SOD were determined to observe the levels of oxidative stress in mice. And Western blot analyses were used to detect content of SIRT1 in mice.ResultsIn the APP/PS mice, after BDMC intervention, their cognitive function improved, oxidative stress adjusted, the number of neurons increased, Aβ deposition decreased, and the level of SIRT1 expression increased. However, when SIRT1 is inhibited, BDMC on the improvement in the learning and memory ability and the improvement on oxidative stress in APP/PS1 mice were reversed.ConclusionOur findings demonstrated that in the AD mice, BDMC has antagonistic effect on AD. And an intermediate step in the antagonism effect is caused by SIRT1 upregulation, which leading to decreased oxidative stress. Based on these, we concluded that BDMC injection into the lateral ventricle can act against AD by upregulating SIRT1 to antioxidative stress.
Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
Authors: Matsuki Takashi , Okamoto Isaku , Fushimi Chihiro , Sawabe Michi , Kawakita Daisuke , Sato Hiroki , Tsukahara Kiyoaki , Kondo Takahito , Okada Takuro , Tada Yuichiro , Miura Kouki , Omura Go , Yamashita Taku 
Published: May 2020

AbstractBackgroundThere is increasing evidence that immunotherapy with nivolumab, an anti‐programmed death 1 monoclonal antibody, is effective in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the predictive role of hematological inflammatory markers such as neutrophil‐to‐lymphocyte ratio (NLR) and the modified Glasgow prognostic score (mGPS) in patients with R/M SCCHN treated with nivolumab remains unclear.MethodsWe conducted a multi‐institutional cohort study to evaluate the impact of pretreatment NLR and mGPS on overall survival (OS) and progression‐free survival (PFS) in patients with R/M SCCHN treated with nivolumab in Japan. From 2012 to 2013, 102 patients were eligible, of whom 88 were finally included in the analysis. mGPS was calculated as follows: mGPS of 0, C‐reactive protein (CRP) ≤1.0 mg/dL; 1, CRP > 1.0 mg/dL; and 2, CRP > 1.0 mg/dL and albumin < 3.5 mg/dL. Optimal cutoff point of dichotomized NLR was calculated using the area under the receiver operating characteristic curve (AUROC). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated by Cox proportional hazard models adjusted by potential confounders.ResultsHigher NLR was significantly associated with worse survival (1‐year OS: 45.3% vs 16.3%, log‐rank P‐value < .001, adjusted HR: 4.40 (95% CIs: 1.78‐10.88); one‐year PFS: 39.1% vs 9.0%, P‐value = .001, adjusted HR: 3.37 (95% CI: 1.64‐6.92)). In addition, high mGPS (=2) was significantly associated with worse survival compared to low mGPS (=0) (1‐year OS: 37.4% vs 26.1%, P‐value = .004, adjusted HR: 4.20 (95% CI:1.54‐11.49); 1‐year PFS: 41.5% vs 24.8%, P‐value = .007, adjusted HR: 2.01 (95% CI: 0.87‐4.68)). These associations were consistent with subgroup analyses stratified by potential confounders.ConclusionsPretreatment NLR and mGPS might be predictive markers of survival in patients with R/M SCCHN treated with nivolumab.
Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: An IMPACT Cohort Study
Authors: Gupta Sumit , Baxter Nancy N. , Hodgson David , Punnett Angela , Sutradhar Rinku , Pole Jason D. , Nagamuthu Chenthila , Lau Cindy , Nathan Paul C. 
Published: May 2020

AbstractHodgkin lymphoma (HL) is a common adolescent and young adult (AYA) cancer. While outcome disparities between pediatric vs. adult centers [locus of care (LOC)] have been demonstrated in other AYA cancers such as acute lymphoblastic leukemia, they have not been well studied in HL. We therefore compared population‐based treatment patterns and outcomes in AYA HL by LOC. The IMPACT Cohort includes data on all Ontario, Canada AYA (15‐21 years) diagnosed with HL between 1992 and 2012. Linkage to population‐based health administrative data identified late effects. We examined LOC‐based differences in treatment modalities, cumulative doses, event‐free survival (EFS), overall survival (OS), and late effects. Among 954 AYA, 711 (74.5%) received therapy at adult centers. Pediatric center AYA experienced higher rates of radiation therapy but lower cumulative doses of doxorubicin and bleomycin. 10‐year EFS did not differ between pediatric vs. adult cancer vs. community centers (83.8% ± 2.4% vs. 82.8% ± 1.6% vs. 82.7%±3.0%; P = .71); LOC was not significantly associated with either EFS or OS in multivariable analyses. Higher incidences of second malignancies in pediatric center AYA and of cardiovascular events in adult center AYA were observed, but were not significant. In conclusion, while pediatric and adult centers used different treatment strategies, outcomes were equivalent. Differences in treatment exposures are however likely to result in different late‐effect risks. Protocol choice should be guided by individual late‐effect risk.
Reduced expression of CYLD promotes cell survival and inflammation in gefitinib‐treated NSCLC PC‐9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy
Authors: Yuan Yuan , Liu Liu , Wang Yi , Liu Shangquan 
Published: May 2020

AbstractThe application of tyrosine kinase inhibitors (TKIs) to the epidermal growth factor receptor (EGFR) has been proven to be highly effective for non‐small‐cell lung cancer (NSCLC). However, patients often evolve into acquired resistance. The secondary mutations in EGFR account for nearly half of the acquired resistance. While the remaining 50% of patients exhibit tolerance to EGFR‐TKIs with unclear mechanism(s). Cylindromatosis (CYLD), a deubiquitinase, functions as a tumor suppressor to regulate cell apoptosis, proliferation, and immune response, and so on. The role of CYLD in NSCLC EGFR‐TKI resistance remains elusive. Here, we found CYLD was upregulated in PC‐9 cells, whereas downregulated in PC‐9 acquired gefitinib‐resistant (PC‐9/GR) cells in response to the treatment of gefitinib, which is consistent with the results in the Gene Expression Omnibus database. Overexpression of CYLD promoted a more apoptotic death ratio in PC‐9/GR cells than that in PC‐9 cells. In addition, silencing the expression of CYLD resulted in an increase of the expression level of interleukin‐6, transforming growth factor‐β and tumor necrosis factor‐α, which may contribute to acquired resistance of PC‐9 cells to gefitinib. Taken together, our data in vitro demonstrate that PC‐9/GR cells downregulated CYLD expression, enhanced subsequent CYLD‐dependent antiapoptotic capacity and inflammatory response, which may provide a possible target for acquired gefitinib‐resistant treatment in NSCLC.
Stepwise Assembly of an Electroactive Framework from a Co6S8 Superatomic Metalloligand and Cuprous Iodide Building Units
Authors: Freeman Matthew B. , Edokobi Ozioma D. , Gillen Jonathan H. , Kocherga Margaret , Dipple Kathleen M. , Jones Daniel S. , Paley Daniel W. , Wang Le , Bejger Christopher M. 
Published: May 2020

AbstractThe design of metal–organic frameworks (MOFs) that incorporate more than one metal cluster constituent is a challenging task. Conventional one‐pot reaction protocols require judicious selection of ligand and metal ion precursors, yet remain unpredictable. Stable, preformed nanoclusters, with ligand shells that can undergo additional coordination‐driven reactions, provide a platform for assembling multi‐cluster solids with precision. Herein, a discrete Co6S8(PTA)6 (PTA=1,3,5‐triaza‐7‐phosphaadamantane) superatomic‐metalloligand is assembled into a three‐dimensional (3D) coordination polymer comprising Cu4I4 secondary building units (SBUs). The resulting heterobimetallic framework (1) contains two distinct cluster constituents and bifunctional PTA linkers. Solid‐state diffuse reflectance studies reveal that 1 is an optical semiconductor with a band‐gap of 1.59 eV. Framework‐modified electrodes exhibit reversible redox behavior in the solid state arising from the Co6S8 superatoms, which remain intact during framework synthesis.
Low‐Temperature Miniemulsion‐Based Routes for Synthesis of Metal Oxides
Authors: Muñoz‐Espí Rafael , Landfester Katharina 
Published: May 2020

AbstractThe use of miniemulsions containing chemical precursors in the disperse phase is a versatile method to produce nanoparticles and nanostructures of different chemical nature, including not only polymers, but also a variety of inorganic materials. This Minireview focuses on materials in which nanostructures of metal oxides are synthesized in processes that involve the miniemulsion technique in any of the steps. This includes in the first place those approaches in which the spaces provided by nanodroplets are directly used to confine precipitation reactions that lead eventually to oxides. On the other hand, miniemulsions can also be used to form functionalized polymer nanoparticles that can serve either as supports or as controlling agents for the synthesis of metal oxides. Herein, the description of essential aspects of the methods is combined with the most representative examples reported in the last years for each strategy.
Palladium‐Catalyzed Insertion of Ethylene and 1,1‐Disubstituted Difunctional Olefins: An Experimental and Computational Study
Authors: Gaikwad Shahaji R. , Patel Ketan , Deshmukh Satej S. , Mote Nilesh R. , Birajdar Rajkumar S. , Pandole Satish P. , Chugh Jeetender , Chikkali Samir H. 
Published: May 2020

AbstractInsertion or coordination copolymerization of ethylene with di‐substituted olefins is challenging and the choice of di‐substituted mono‐functional olefin versus di‐substituted di‐functional olefin (DDO) appears to be decisive. Here we show that DDO‐inserted species are amenable to ethylene insertion and polymerization. DDOs such as 2‐acetamidoacrylic acid (AAA), methyl 2‐acetamidoacrylate (MAAA), and ethyl 2‐cyanoacrylate (ECA) were treated with palladium complex [{P∧O}PdMe(L)] (P∧O=κ2‐P,O−Ar2PC6H4SO2O with Ar=2‐MeOC6H4; L=C2H6OS) and the existence of respective insertion intermediates in moderate yield (up to 37 %) was established. These intermediates were exposed to ethylene and corresponding ethylene‐inserted products were isolated and characterized. A careful comparison with three model compounds confirmed ethylene insertion and polymerization. Thus, the combined experimental and computational investigations show that DDO‐inserted species can undergo ethylene insertion and polymerization.
Single nucleotide polymorphisms facilitate distinctness‐uniformity‐stability testing of soybean cultivars for plant variety protection
Authors: Achard F. , Butruille M. , Madjarac S. , Nelson P.T. , Duesing J. , Laffont J‐L. , Nelson B. , Xiong J. , Mikel Mark A. , Smith J.S.C. 
Published: May 2020

AbstractPlant variety protection (PVP), or plant breeders’ rights, provides intellectual property protection (IPP) for cultivars. Technical requirements are distinctness, uniformity, and stable (DUS) reproduction. However, field trials are increasingly resource demanding and potentially inconclusive for soybean (Glycine max[L.] Merr.). Our objective was to establish methodologies using molecular markers to facilitate DUS testing while maintaining current IPP levels. We determined that DNA from 10–15 bulked plants represented cultivar genotype. Single nucleotide polymorphism (SNP) data were highly robust in the face of missing and mistyped data; concordances among five laboratories were >.9888. We used SNP, morphological, physiological, and pedigree information to examine 322 publicly available cultivars including 187 with PVPs. Associations among cultivars following multivariate analyses of genetic distances from SNP data and from pedigree kinship data were very similar. A SNP similarity of 98.6% was the maximum at which cultivars also differed for morphological characteristics. Many (38%) cultivar pairs with members >90% SNP similarity expressed different morphologies with SNP similarities ranging 96–98.6%. Of cultivars <96% SNP similar, only a single pair differed by a single morphological difference; all others differed by more than two morphological characteristics. A SNP similarity of 96% between soybean cultivars represents an initial and conservative point of demarcation between cultivars that have morphological differences and those that do not. Chronological monitoring of pedigree–kinship and SNP similarities showed little evidence that a lack of genetic diversity in F2breeding populations contributed to challenges in DUS among U.S. soybean cultivars.
HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion
Authors: Hiroshima Kenzo , Wu Di , Hamakawa Shinji , Tsuruoka Shingo , Ozaki Daisuke , Orikasa Hideki , Hasegawa Mizue , Koh Eitetsu , Sekine Yasuo , Yonemori Yoko , Nabeshima Kazuki , Tsuji Shoutaro , Miyagi Yohei , Imai Kohzoh 
Published: May 2020

AbstractBackgroundThe specificity and sensitivity of HEG1 for malignant mesothelioma (MM) is high. The use of BAP1/MTAP immunohistochemistry (IHC) is recommended to separate benign and malignant mesothelial proliferations. We determined how ancillary techniques can be used for the cytological diagnosis of MM with effusion.MethodsCell blocks from effusions from cases with MM, reactive mesothelial cells (RMCs), and carcinomas were analyzed by IHC with HEG1, BAP1, and MTAP and with homozygous deletion (HD) of CDKN2A by fluorescence in situ hybridization. Staining scores were calculated for IHC by adding the number of categories for the staining intensity and the staining extension.ResultsHEG1 was positive in all (41/41) MMs, but negative in carcinomas, except for ovarian carcinomas. Overall 76.9% (20/26) of RMCs and 28.6% (6/21) of ovarian carcinomas expressed HEG1. BAP1 loss was found in 71.1% of MMs, but none was found in RMCs. MTAP loss was found in 76.2% of MMs, but none was found in RMCs. 73.9% of MMs harbored HD of CDKN2A. There was concordance between loss of MTAP and HD of CDKN2A in 95% of MMs.ConclusionHEG1 is a good marker for mesothelial differentiation in effusion cytology. HD of CDKN2A is frequently observed in cell blocks from effusions of MMs, and MTAP IHC may act as a surrogate for HD of CDKN2A. Cell block analysis is recommended for effusions of unknown origins with the following methods: IHC with HEG1 and claudin 4 to validate the mesothelial origin, followed by BAP1 and MTAP IHC to confirm malignancy.
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial
Authors: Giannoni Alberto , Borrelli Chiara , Mirizzi Gianluca , Richerson George B. , Emdin Michele , Passino Claudio 
Published: May 2020

AimsIncreased chemosensitivity to carbon dioxide (CO2) is an important trigger of central apnoeas (CA) in heart failure (HF), with negative impact on outcome. We hypothesized that buspirone, a 5HT1A receptor agonist that inhibits serotonergic chemoreceptor neuron firing in animals, can decrease CO2 chemosensitivity and CA in
HF.Methods and resultsThe BREATH study was a randomized, double‐blind, placebo‐controlled, crossover study (EudraCT‐code 2015‐005383‐42). Outpatients with systolic HF (left ventricular ejection fraction <50%) and moderate‐severe CA [nocturnal apnoea‐hypopnoea index (AHI) ≥15 events/h] were randomly assigned to either oral buspirone (15 mg thrice daily) or placebo for 1 week, with a crossover design (1 week of wash‐out). The primary effectiveness endpoint was a decrease in CO2 chemosensitivity >0.5 L/min/mmHg. The primary safety endpoint was freedom from serious adverse events. Sixteen patients (age 71.3 ± 5.8 years, all males, left ventricular ejection fraction 29.8 ± 7.8%) were enrolled. In the intention‐to‐treat analysis, more patients treated with buspirone (8/16, 50%) had a CO2 chemosensitivity reduction >0.5 L/min/mmHg from baseline than those treated with placebo (1/16, 6.7%) (difference between groups 43%, 95% confidence interval 14–73%, P = 0.016). Buspirone compared to baseline led to a 41% reduction in CO2 chemosensitivity (P = 0.001) and to a reduction in the AHI, central apnoea index and oxygen desaturation index of 42%, 79%, 77% at nighttime and 50%, 78%, 86% at daytime (all P < 0.01); no difference was observed after placebo administration (all P > 0.05). No patient reported buspirone‐related serious adverse events.ConclusionsBuspirone reduces CO2 chemosensitivity and improves CA and oxygen saturation across the 24 h in patients with
HF.
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
Authors: Packer Milton , Lam Carolyn S.P. , Lund Lars H. , Maurer Mathew S. , Borlaug Barry A. 
Published: May 2020

AbstractAccumulating evidence points to the existence of an inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction (HFpEF), which is characterized by biomarkers of inflammation, an expanded epicardial adipose tissue mass, microvascular endothelial dysfunction, normal‐to‐mildly increased left ventricular volumes and systolic blood pressures, and possibly, altered activity of adipocyte‐associated inflammatory mediators. A broad range of adipogenic metabolic and systemic inflammatory disorders – e.g. obesity, diabetes and metabolic syndrome as well as rheumatoid arthritis and psoriasis – can cause this phenotype, independent of the presence of large vessel coronary artery disease. Interestingly, when compared with men, women are both at greater risk of and may suffer greater cardiac consequences from these systemic inflammatory and metabolic disorders. Women show disproportionate increases in left ventricular filling pressures following increases in central blood volume and have greater arterial stiffness than men. Additionally, they are particularly predisposed to epicardial and intramyocardial fat expansion and imbalances in adipocyte‐associated proinflammatory mediators. The hormonal interrelationships seen in inflammatory‐metabolic phenotype may explain why mineralocorticoid receptor antagonists and neprilysin inhibitors may be more effective in women than in men with HFpEF. Recognition of the inflammatory‐metabolic phenotype may improve an understanding of the pathogenesis of HFpEF and enhance the ability to design clinical trials of interventions in this heterogeneous syndrome.
Relationship between T cell receptor clonotype and PD‐1 expression of tumor‐infiltrating lymphocytes in colorectal cancer
Authors: Sukegawa Kenta , Shitaoka Kiyomi , Hamana Hiroshi , Kobayashi Eiji , Miyahara Yoshihiro , Fujii Keisuke , Tsuda Kei , Saeki Shiori , Nagata Takuya , Ozawa Tatsuhiko , Saito Shigeru , Fujii Tsutomu , Muraguchi Atsushi , Shiku Hiroshi , Kishi Hiroyuki 
Published: May 2020

AbstractAdoptive T cell therapy using tumor‐specific T cells or TCR‐modified T cells is a promising next‐generation immunotherapy. The major source of tumor‐reactive T cells is PD‐1+ tumor‐infiltrating lymphocytes (TILs). In contrast, PD‐1− TILs have received little attention. Here, we analyzed the TCR‐β repertoires of PD‐1− and PD‐1+ CD8+ TILs derived from colorectal cancer and breast cancer. Approximately 40–60% of the PD‐1+ population consisted of oligoclonal populations in both colorectal cancer and breast cancer. In contrast, approximately 37% of the PD‐1− population consisted of an oligoclonal population in colorectal cancer, whereas 14% of them were oligoclonal in breast cancer. In colorectal cancer, the TCR repertoires of PD‐1−CD8+ TILs and PD‐1+CD8+ TILs hardly overlapped. Interestingly, clonally expanded CD8+ TILs in primary tumors and the metastases expressing the same clonotypic TCR showed the same phenotype regarding the PD‐1‐expression. These results suggest that the intrinsic properties of TCRs determine the fate of TILs in terms of whether they become PD‐1+ or PD‐1− in the tumor microenvironment. Further functional analysis of TCRs in TILs will allow us to better understand the regulatory mechanisms for PD‐1 expression on TILs and may contribute to tumor immunotherapy.
Preparation of methylammonium lead iodide (CH3NH3PbI3) thin film perovskite solar cells by chemical vapor deposition using methylamine gas (CH3NH2) and hydrogen iodide gas
Authors: Mortan Claudiu , Hellmann Tim , Buchhorn Moritz , d'Eril Melzi Marco , Clemens Oliver , Mayer Thomas , Jaegermann Wolfram 
Published: May 2020

AbstractAn upscalable chemical vapor deposition setup has been built‐up and employed in producing methylammonium lead iodide (MAPI) thin film perovskite solar cells, leading to a maximum efficiency of 12.9%. The method makes use of methylamine gas and hydrogen iodide gas to transform a predeposited layer of lead(II)iodide (PbI2) into MAPI. Although the reaction mechanism includes the intermediate phases lead oxide (PbO) and lead hydroxide (Pb(OH)2), indicated at least on the surface of the samples by XPS, neither species could be observed in XRD measurements of the stepwise reaction, which show a mixture of highly oriented cubic and tetragonal MAPI perovskite lattice systems.